Phenotypes, genotypes, and prevalence of congenital myopathies older than 5 years in Denmark

Nanna Witting, Ulla Werlauff, Morten Duno, John Vissing, Nanna Witting, Ulla Werlauff, Morten Duno, John Vissing

Abstract

Objective: Congenital myopathy as a nosologic entity has long been recognized, but knowledge of overall and subtype prevalence and phenotype-genotype relationship is scarce, especially in the adult population.

Methods: A national cohort of 107 patients ≥5 years diagnosed with congenital myopathy were prospectively assessed clinically, histologically, and genetically.

Results: Twenty-five patients were excluded because of atypical features or alternative etiologies. The remaining 82 were on average 28 years old. Histologic examination revealed 14 (17%) with core disease, 15 (18%) centronuclear myopathy, 12 (15%) nemaline rods, 27 (33%) congenital fiber-type disproportion or type I predominance, and 14 (17%) nonspecific myopathic changes. Genetic etiology was identified in 46 patients (56.1%); 22.0% were heterozygous or compound heterozygous for mutations in RYR1, 7.3% had DNM2 mutations, and 7.3% NEB mutations. Less than 5% had mutations in ACTA1, TPM2/3, MTM1, TTN, SEPN1, or SC4NA. A genetic cause was established in 83% with specific histology (cores/rods/centronuclear myopathy) vs 29% with unspecific histology. The detailed clinical examination found gene-dependent discrepancies in the pattern of muscle affection and walking ability. Although walking ability was delayed in patients with ACTA1, TPM2/3, and RYR1 mutations, it was within normal limits in patients with NEB and DNM2 mutations.

Conclusions: We found that overall, genetic and histologic prevalence of congenital myopathy in Denmark differs from previous retrospective reports. Less RYR1 and more DNM2 and NEB mutations and less core histology were present in our cohort. These differences may be explained by our prospective design, the older cohort of patients, and by differences in genetic background.

Figures

Figure 1. Patient flow
Figure 1. Patient flow
ACTA1 = skeletal muscle α-actin 1; AD = autosomal dominant; AR = autosomal recessive; CK = creatine kinase; CMS = congenital myasthenic syndrome; DES = desmin; DNM2 = dynamin 2; DOK7 = downstream-of-kinase 7 myasthenic syndrome; LGMD = limb-girdle muscular dystrophy; MTM1 = myotubularin 1; NEB = nebulin; RAPSN = receptor-associated protein of the synapse myasthenic syndrome; RYR1 = ryanodine receptor 1; SCN4A = sodium channel 4A; SEPN1 = selenoprotein 1; TPM2/3 = tropomyosin 2/3; TTN = titin. *Of these 6, 1 had LGMD2L, 1 LGMD2A, and 1 LGMD1C.
Figure 2. Detailed muscle strength and vital…
Figure 2. Detailed muscle strength and vital capacity in various genetic subtypes of congenital myopathy
For Medical Research Council (MRC); gray bars left side, black bars right side. Bottom: forced vital capacity (FVC) in percentage of expected normal values.

References

    1. Maggi L, Scoto M, Cirak S, et al. . Congenital myopathies—clinical features and frequency of individual subtypes diagnosed over a 5-year period in the United Kingdom. Neuromuscul Disord 2013;23:195–205.
    1. Colombo I, Scoto M, Manzur AY, et al. . Congenital myopathies: natural history of a large pediatric cohort. Neurology 2015;84:28–35.
    1. Pelin K, Hilpela P, Donner K, et al. . Mutations in the nebulin gene associated with autosomal recessive nemaline myopathy. Proc Natl Acad Sci USA 1999;96:2305–2310.
    1. Brandt A, Schleithoff L, Jurkat-Rott K, Klingler W, Baur C, Lehmann-Horn F. Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture test. Hum Mol Genet 1999;8:2055–2062.
    1. Carmignac V, Salih MA, Quijano-Roy S, et al. . C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. Ann Neurol 2007;61:340–351.
    1. Hackman P, Vihola A, Haravuori H, et al. . Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. Am J Hum Genet 2002;71:492–500.
    1. Romero NB, Clarke NF. Congenital myopathies. Handb Clin Neurol 2013;113:1321–1336.
    1. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy: I: the design of the protocol. Muscle Nerve 1981;4:186–197.
    1. Lohmueller KE, Sparso T, Li Q, et al. . Whole-exome sequencing of 2,000 Danish individuals and the role of rare coding variants in type 2 diabetes. Am J Hum Genet 2013;93:1072–1086.
    1. Klein A, Lillis S, Munteanu I, et al. . Clinical and genetic findings in a large cohort of patients with ryanodine receptor 1 gene-associated myopathies. Hum Mutat 2012;33:981–988.
    1. Hughes MI, Hicks EM, Nevin NC, Patterson VH. The prevalence of inherited neuromuscular disease in Northern Ireland. Neuromuscul Disord 1996;6:69–73.
    1. Darin N, Tulinius M. Neuromuscular disorders in childhood: a descriptive epidemiological study from western Sweden. Neuromuscul Disord 2000;10:1–9.
    1. Amburgey K, McNamara N, Bennett LR, McCormick ME, Acsadi G, Dowling JJ. Prevalence of congenital myopathies in a representative pediatric United States population. Ann Neurol 2011;70:662–665.
    1. Sveen ML, Schwartz M, Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol 2006;59:808–815.
    1. Norwood FL, Harling C, Chinnery PF, Eagle M, Bushby K, Straub V. Prevalence of genetic muscle disease in Northern England: in-depth analysis of a muscle clinic population. Brain 2009;132:3175–3186.
    1. Hong D, Wang Z, Zhang W, et al. . A series of Chinese patients with desminopathy associated with six novel and one reported mutations in the desmin gene. Neuropathol Appl Neurobiol 2011;37:257–270.
    1. North KN, Laing NG. Skeletal muscle alpha-actin diseases. Adv Exp Med Biol 2008;642:15–27.
    1. Wallgren-Pettersson C, Lehtokari VL, Kalimo H, et al. . Distal myopathy caused by homozygous missense mutations in the nebulin gene. Brain 2007;130:1465–1476.
    1. North KN, Wang CH, Clarke N, et al. . Approach to the diagnosis of congenital myopathies. Neuromuscul Disord 2014;24:97–116.
    1. Bohm J, Biancalana V, Dechene ET, et al. . Mutation spectrum in the large GTPase dynamin 2, and genotype-phenotype correlation in autosomal dominant centronuclear myopathy. Hum Mutat 2012;33:949–959.
    1. Citirak G, Witting N, Duno M, Werlauff U, Petri H, Vissing J. Frequency and phenotype of patients carrying TPM2 and TPM3 gene mutations in a cohort of 94 patients with congenital myopathy. Neuromuscul Disord 2014;24:325–330.
    1. Werlauff U, Petri H, Witting N, Vissing J. Frequency and phenotype of myotubular myopathy amongst Danish patients with congenital myopathy older than 5 years. J Neuromusc Dis 2015;2:167–174.
    1. Witting N, Werlauff U, Duno M, Vissing J. Prevalence and phenotypes of congenital myopathy due to alpha-actin 1 gene mutations. Muscle Nerve 2016;53:388–393.
    1. Zaharieva IT, Thor MG, Oates EC, et al. . Loss-of-function mutations in SCN4A cause severe foetal hypokinesia or “classical” congenital myopathy. Brain 2016;139:674–691.
    1. Kaplan JC, Hamroun D. The 2015 version of the gene table of monogenic neuromuscular disorders (nuclear genome). Neuromuscul Disord 2014;24:1123–1153.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel